Navigation Links
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Date:6/17/2011

ST. LOUIS, June 17, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has entered into a definitive agreement to divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc. for approximately $60 million in cash. The transaction is estimated to close during the second quarter of KV's 2012 fiscal year, subject to customary closing conditions.

The divesture of the Company's generic business has been an important goal of KV's Board of Directors and Management team.  The completion of this divestiture is an important element of the Company's declared strategy of transitioning to a branded specialty pharmaceutical company focused on women's health.  

Jefferies & Company, Inc. acted as exclusive financial advisor to K-V in this transaction.

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare.   As such, we are committed to advancing the health of women across all the stages of their lives.

For further information about K-V Pharmaceutical Company, please visit the Company's corporate Website at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

This press release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and that may be based on or include assumptions concerning the operations, future results and prospects of the Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Selexis SA announced today the Company,s president ... Biotech Showcase 2012 Conference held in conjunction with the ... Dr. Fisch will present, "Translating Drug Discovery ... and corporate partners on Monday, January 9 at 11:00 ...
... and AMSTERDAM, Jan. 5, 2012  Agendia, an innovative ... company has signed a contract with Blue Shield ... move paves the way for future in-network coverage ... Cross affiliates across the United States. Developed and ...
... 2012 WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic ... deliver its corporate presentation at the 5 th ... Drake Hotel, San Francisco, Calif., January 9-12, 2012. ... January 10, 2012 beginning at 10:00 a.m. Pacific Time.  ...
Cached Biology Technology:Selexis SA to Present at Biotech Showcase 2012 2Agendia Signs Contract with Blue Shield of California 2WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
(Date:10/15/2014)... ability to assess the pandemic risk from strains of ... must not allow ourselves to become complacent that the ... consortium of scientists. , Influenza pandemics arise when a ... to develop widespread immunity – spreads in the human ... past 100 years, the worst of which – the ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... The location of an underwater volcanic vent, marked by ... by scientists at the National Oceanography Centre, Southampton. ... the researchers describe how the vent, discovered in a ... we have come to recognise as "classic" hydrothermal vents. ...
... fish are more likely to accept immigrants into their group ... new research shows. The researcher suggests that there are parallels ... research was published today, 6 February 2013, in the journal ... The Princess of Lake Tanganyika ( Neolamprologus pulcher ), a ...
... NEW YORK , Feb. 5, 2013 ... research report is available in its catalogue: ... Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 ... Vascular Endothelial Growth Factor (VEGF), which ...
Cached Biology News:Shimmering water reveals cold volcanic vent in Antarctic waters 2Environmental factors determine whether immigrants are accepted by cooperatively breeding animals 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 3VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 4VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 5
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
... Rabbit polyclonal to MSY2/YBOX2 ( ... Antigen: Synthetic ... amino acids 178-227 of human YBX2. ... sequence is proprietary). ...
Standard Fluka For microscopy (Bact., Hist.)...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
Biology Products: